Catalyst by Wellstar Invests in Armor Medical to Transform Maternal Health
Catalyst by Wellstar has invested in Armor Medical to accelerate the development of Maternal aRMOR, a wearable device designed to detect postpartum hemorrhage in real time. Learn how this collaboration is driving forward innovation to save mothers’ lives and redefine maternal care.
6/24/20252 min read
ATLANTA, GA – June 24, 2025 – Armor Medical is proud to announce a strategic investment from Catalyst by Wellstar, the innovation and venture arm of Wellstar Health System, to accelerate the development and deployment of its breakthrough maternal health technology, Maternal aRMOR.
Catalyst recently spotlighted the urgency of this mission in a feature article titled “This Wearable Could Help End a Leading Cause of Maternal Death”, underscoring why they are backing our work and what’s at stake: postpartum hemorrhage (PPH) remains the leading cause of maternal death worldwide—and most of these deaths are preventable.
Why This Matters
Every year, 14 million women globally experience PPH. Despite being the leading cause of maternal death, most of these outcomes are preventable. Yet current tools rely on delayed and inaccurate indicators like visual blood loss estimation and vital sign changes—often when it’s already too late.
At Armor Medical, we’re building a new standard of care.
The Innovation: Maternal aRMOR
Maternal aRMOR is a wrist-worn device that uses advanced light-based sensors and imaging to continuously track changes in peripheral blood flow—the earliest signs of hemorrhage, even before blood pressure drops. It’s:
Non-invasive
Real-time
Designed for seamless hospital integration
With clinical studies and FDA clearance on the horizon, we’re focused on bringing this life-saving technology to market by 2027.
A Mission Backed by Catalyst
Catalyst by Wellstar is more than an investor—they’re a partner in purpose. Their support is enabling us to conduct frontline research with nurses, explore system integration, and design for real-world implementation from day one.
“By investing in solutions that enable real-time detection and intervention, we’re not just funding innovation—we are helping save lives.”
— Jaimie Clark, Head of Innovation, Catalyst by Wellstar
This partnership strengthens our ability to bring Maternal aRMOR to providers and patients where it’s needed most.
Looking Ahead
We’re honored to be supported by mission-aligned organizations like Catalyst and early believers like Femovate, who have helped shape our technology and vision. Together, we’re working toward a future where no mother dies from preventable bleeding—and where every birth is safer.
🔗 Read the full Catalyst by Wellstar feature
🔗 Learn more about Maternal aRMOR
🔗 Contact us to partner or learn more
